Sage Therapeutics (NASDAQ:SAGE) stock drops as Bank of America issues an Underperform rating citing an end to Biogen's (BIIB) ...

BofA resumed coverage of Sage Therapeutics (SAGE) with an Underperform rating and $5 price target. The impact of Biogen’s (BIIB) unsolicited ...

As Sage Therapeutics Inc. contemplates its path forward after rejecting a buyout offer from Biogen, its top executive ...

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...

Bank of America started coverage on shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) in a report released on Tuesday. The brokerage issued an underperform rating and a $5.00 target price on the ...

Sage Therapeutics, Inc. SAGE reported a loss of $1.56 per share for the fourth quarter of 2024, wider than the Zacks Consensus Estimate of a loss of $1.45. The company had reported a loss of 55 ...

Philadelphia, Pennsylvania-- (Newsfile Corp. - March 8, 2025) - Grabar Law Office is investigating claims on behalf of Sage Therapeutics, Inc. (NASDAQ: SAGE) shareholders. The investigation concerns ...

We recently published a list of 10 Best Small-Cap Growth Stocks to Buy Now. In this article, we are going to take a look at where Sage Therapeutics, Inc.

Sage Therapeutics, Inc. (NASDAQ:SAGE – Get Free Report) has been given a consensus recommendation of “Hold” by the nineteen ratings firms that are currently covering the stock, MarketBeat.com reports.

https://www.tipranks.com/news/the-fly/medtronic-price-target-raised-to-93-from-89-at-truist Scotiabank lowered the firm’s price target on Sage Therapeutics (SAGE ...

Sage is focused on the goal of establishing ZURZUVAE as the standard of care for women with postpartum depression (PPD). The current commercialization investment plan includes joint sales force ...

Sage Chief Medical Officer Laura Gault, M.D., Ph.D., is stepping down to pursue a new opportunity effective March 21, the ...